Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $668.5K in total
- 2
- 13F holdersQ2 2026, +44 vs. previous quarter
- 267
- 13F valueReported value at the end of Q2 2026
- $2.99B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KNSA, Q2 2026
No superinvestor reported holding KNSA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Kiniksa Pharmaceuticals International, plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:40 PM ET | Sep 3 | Same day | Megna Michael RCHIEF ACCOUNTING OFFICER | SSaleClass A Ordinary Share | −4.60K | $80.30 | −$369.4K | −13.7%29.1K after | 10b5-1 |
| Jul 31, 2026 (view filing)4:34 PM ET | Jul 29 | 2 days | Cole G BradleyDirector | SSaleClass A Ordinary Share | −3.67K | $81.43 | −$299.1K | −23.9%11.7K after | |
| May 5, 2026 (view filing) | May 1 | 4 days | Paolini John F.CHIEF MEDICAL OFFICER | SSaleClass A Ordinary Share | −58.4K | $53.71 | −$3.14M | −47.1%65.6K after | 2 lots10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −48.6K | $54.02 | −$2.62M | −100.0%0 after | 10b5-1 |
| Apr 30, 2026 (view filing) | Apr 28-30 | 2 days | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −508.3K | $51.96 | −$26.4M | −100.0%0 after | 6 lots10b5-1 |
| Apr 29, 2026 (view filing) | Apr 28 | 1 day | Quart Barry DDirector | SSaleClass A Ordinary Share | −13.1K | $50.10 | −$656.3K | −51.1%12.5K after | 10b5-1 |
| Apr 13, 2026 (view filing) | Apr 9 | 4 days | Moat RossCHIEF OPERATING OFFICER | SSaleClass A Ordinary Share | −1.70K | $46.69 | −$79.5K | −12.4%12.0K after | 10b5-1 |
| Apr 13, 2026 (view filing) | Apr 9 | 4 days | Megna Michael RCHIEF ACCOUNTING OFFICER | SSaleClass A Ordinary Share | −6.63K | $46.69 | −$309.3K | −19.5%27.4K after | 10b5-1 |
| Apr 8, 2026 (view filing) | Apr 6 | 2 days | Moat RossCHIEF OPERATING OFFICER | SSaleClass A Ordinary Share | −2.37K | $48.58 | −$115.0K | −16.4%12.0K after | 10b5-1 |
| Apr 8, 2026 (view filing) | Apr 6 | 2 days | Patel Sanj KCHAIRMAN & CEO | SSaleClass A Ordinary Share | −7.28K | $50.01 | −$364.0K | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Kiniksa Pharmaceuticals International, plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,971,361 | $445.8M | 0.02% | +147,661+2.2% | Added |
| Rubric Capital Management LP | 3,999,800 | $255.8M | 2.35% | +249,800+6.7% | Added |
| Baker Bros. Advisors LP | 2,834,643 | $181.3M | 0.91% | +8,397+0.3% | Added |
| BlackRock, Inc. | 2,739,615 | $175.2M | 0.00% | +2,252,878+462.9% | Added |
| Tang Capital Management LLC | 2,259,889 | $144.5M | 6.56% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 1,911,335 | $122.2M | 0.01% | +145,067+8.2% | Added |
| Vanguard Capital Management LLC | 1,360,840 | $87.0M | 0.00% | +27,747+2.1% | Added |
| Morgan Stanley | 1,011,143 | $64.7M | 0.00% | +13,357+1.3% | Added |
| Arrowstreet Capital, Limited Partnership | 957,514 | $61.2M | 0.03% | +64,848+7.3% | Added |
| Spruce Street Capital LP | 918,070 | $58.7M | 11.52% | +157,007+20.6% | Added |